Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042908-09
Application #
2090999
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1987-05-01
Project End
1998-11-30
Budget Start
1995-12-01
Budget End
1996-11-30
Support Year
9
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107

  Publications

Sharp, Daniel W; Lattime, Edmund C (2016) Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. Biomedicines 4:
de Vries, C R; Monken, C E; Lattime, E C (2015) The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther 22:154-62
Nikitczuk, Kevin P; Schloss, Rene S; Yarmush, Martin L et al. (2013) PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-? response and enhances survival. J Cancer Ther 4:280-290
Moloughney, Joseph G; Monken, Claude E; Tao, Hanlin et al. (2011) Vaccinia virus leads to ATG12–ATG3 conjugation and deficiency in autophagosome formation. Autophagy 7:1434-47
Nikitczuk, Kevin P; Lattime, Edmund C; Schloss, Rene S et al. (2010) ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR 1-METHYL TRYPTOPHAN. Nano Life 1:239-250
Yang, Arvin S; Lattime, Edmund C (2003) Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63:2150-7
Yang, Arvin S; Monken, Claude E; Lattime, Edmund C (2003) Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res 63:6956-61
Mastrangelo, Michael J; Lattime, Edmund C (2002) Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther 9:1013-21
Mastrangelo, M J; Eisenlohr, L C; Gomella, L et al. (2000) Poxvirus vectors: orphaned and underappreciated. J Clin Invest 105:1031-4
Mastrangelo, M J; Maguire Jr, H C; Eisenlohr, L C et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6:409-22

Showing the most recent 10 out of 13 publications